JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 103 filers reported holding JOUNCE THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.82 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $37 | -100.0% | 33,430 | 0.0% | 0.00% | -60.0% |
| Q3 2022 | $78,000 | -22.8% | 33,430 | 0.0% | 0.01% | -37.5% |
| Q2 2022 | $101,000 | +32.9% | 33,430 | +227.7% | 0.01% | -20.0% |
| Q3 2021 | $76,000 | -59.4% | 10,200 | -62.3% | 0.01% | -84.1% |
| Q2 2020 | $187,000 | -2.6% | 27,090 | -33.0% | 0.06% | -22.2% |
| Q1 2020 | $192,000 | -13.1% | 40,410 | +59.7% | 0.08% | +22.7% |
| Q4 2019 | $221,000 | +163.1% | 25,310 | 0.0% | 0.07% | +112.9% |
| Q3 2019 | $84,000 | -42.1% | 25,310 | -13.8% | 0.03% | -42.6% |
| Q2 2019 | $145,000 | +64.8% | 29,360 | +107.0% | 0.05% | +8.0% |
| Q1 2019 | $88,000 | – | 14,182 | – | 0.05% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 9,200,349 | $64,402,000 | 44.86% |
| TRV GP III, LLC | 3,048,780 | $21,342,000 | 1.83% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 406,665 | $2,847,000 | 1.65% |
| Sofinnova Investments, Inc. | 925,280 | $6,477,000 | 0.39% |
| Omega Fund Management, LLC | 334,965 | $2,345,000 | 0.35% |
| Yorktown Management & Research Co Inc | 49,200 | $344,000 | 0.31% |
| Woodline Partners LP | 940,902 | $6,586,000 | 0.18% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 51,000 | $357,000 | 0.09% |
| HORIZON FINANCIAL SERVICES, LLC | 12,005 | $84,000 | 0.08% |
| Gyon Technologies Capital Management, LP | 26,893 | $188,000 | 0.06% |